#pharmacometrics — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #pharmacometrics, aggregated by home.social.
-
New from the R Consortium’s nlmixr2 Working Group: adaptive dosing in `rxode2`.
nlmixr2 is an open-source R ecosystem for nonlinear mixed-effects modeling and pharmacometrics, used to model drug behavior and support dose optimization.
Matthew Fidler shows how event tables can respond dynamically to a patient’s trajectory — enabling dose holds, reductions, rescue infusions, and other protocol-driven changes during simulation.
-
New from the R Consortium’s nlmixr2 Working Group: adaptive dosing in `rxode2`.
nlmixr2 is an open-source R ecosystem for nonlinear mixed-effects modeling and pharmacometrics, used to model drug behavior and support dose optimization.
Matthew Fidler shows how event tables can respond dynamically to a patient’s trajectory — enabling dose holds, reductions, rescue infusions, and other protocol-driven changes during simulation.
-
New from the R Consortium’s nlmixr2 Working Group: adaptive dosing in `rxode2`.
nlmixr2 is an open-source R ecosystem for nonlinear mixed-effects modeling and pharmacometrics, used to model drug behavior and support dose optimization.
Matthew Fidler shows how event tables can respond dynamically to a patient’s trajectory — enabling dose holds, reductions, rescue infusions, and other protocol-driven changes during simulation.
-
New from the R Consortium’s nlmixr2 Working Group: adaptive dosing in `rxode2`.
nlmixr2 is an open-source R ecosystem for nonlinear mixed-effects modeling and pharmacometrics, used to model drug behavior and support dose optimization.
Matthew Fidler shows how event tables can respond dynamically to a patient’s trajectory — enabling dose holds, reductions, rescue infusions, and other protocol-driven changes during simulation.
-
The R Consortium #nlmixr2 Working Group on admixr2: fit PK/PD models to published aggregate data when patient-level data aren't available.
Supports digitized mean±SD profiles, published NLME models (MBMA), and joint multi-study fits via nlmixr2/rxode2.
Cross-post: https://r-consortium.org/posts/fitting-pk-pd-models-to-published-data-with-admixr2/
Explore Working Groups: https://r-consortium.org/all-projects/isc-working-groups.html
-
The R Consortium #nlmixr2 Working Group on admixr2: fit PK/PD models to published aggregate data when patient-level data aren't available.
Supports digitized mean±SD profiles, published NLME models (MBMA), and joint multi-study fits via nlmixr2/rxode2.
Cross-post: https://r-consortium.org/posts/fitting-pk-pd-models-to-published-data-with-admixr2/
Explore Working Groups: https://r-consortium.org/all-projects/isc-working-groups.html
-
The R Consortium #nlmixr2 Working Group on admixr2: fit PK/PD models to published aggregate data when patient-level data aren't available.
Supports digitized mean±SD profiles, published NLME models (MBMA), and joint multi-study fits via nlmixr2/rxode2.
Cross-post: https://r-consortium.org/posts/fitting-pk-pd-models-to-published-data-with-admixr2/
Explore Working Groups: https://r-consortium.org/all-projects/isc-working-groups.html
-
The R Consortium #nlmixr2 Working Group on admixr2: fit PK/PD models to published aggregate data when patient-level data aren't available.
Supports digitized mean±SD profiles, published NLME models (MBMA), and joint multi-study fits via nlmixr2/rxode2.
Cross-post: https://r-consortium.org/posts/fitting-pk-pd-models-to-published-data-with-admixr2/
Explore Working Groups: https://r-consortium.org/all-projects/isc-working-groups.html
-
New nlmixr2 blog post: Fitting PK/PD models to published data with admixr2
admixr2 lets you fit PK/PD models to aggregate & published data — digitized mean±SD fits, model-based data generation via datagen(), and joint MBMA across studies.
By H. van de Beek
-
New nlmixr2 blog post: Fitting PK/PD models to published data with admixr2
admixr2 lets you fit PK/PD models to aggregate & published data — digitized mean±SD fits, model-based data generation via datagen(), and joint MBMA across studies.
By H. van de Beek
-
New from the R Consortium nlmixr2 Working Group:
The nlmixr2 Working Group is expanding what open-source R tooling can support in pharmacometrics, including time-to-event modeling workflows that are important in clinical and drug-development settings.
This new post highlights technical work from Justin Wilkins and the nlmixr2 Development Team on fitting parametric time-to-event models in nlmixr2.
Read more:
https://r-consortium.org/posts/survival-analysis-with-nlmixr2/#RStats #Pharmacometrics #PKPD #ClinicalResearch #OpenSource
-
New from the R Consortium nlmixr2 Working Group:
The nlmixr2 Working Group is expanding what open-source R tooling can support in pharmacometrics, including time-to-event modeling workflows that are important in clinical and drug-development settings.
This new post highlights technical work from Justin Wilkins and the nlmixr2 Development Team on fitting parametric time-to-event models in nlmixr2.
Read more:
https://r-consortium.org/posts/survival-analysis-with-nlmixr2/#RStats #Pharmacometrics #PKPD #ClinicalResearch #OpenSource
-
New from the R Consortium nlmixr2 Working Group:
The nlmixr2 Working Group is expanding what open-source R tooling can support in pharmacometrics, including time-to-event modeling workflows that are important in clinical and drug-development settings.
This new post highlights technical work from Justin Wilkins and the nlmixr2 Development Team on fitting parametric time-to-event models in nlmixr2.
Read more:
https://r-consortium.org/posts/survival-analysis-with-nlmixr2/#RStats #Pharmacometrics #PKPD #ClinicalResearch #OpenSource
-
New from the R Consortium nlmixr2 Working Group:
The nlmixr2 Working Group is expanding what open-source R tooling can support in pharmacometrics, including time-to-event modeling workflows that are important in clinical and drug-development settings.
This new post highlights technical work from Justin Wilkins and the nlmixr2 Development Team on fitting parametric time-to-event models in nlmixr2.
Read more:
https://r-consortium.org/posts/survival-analysis-with-nlmixr2/#RStats #Pharmacometrics #PKPD #ClinicalResearch #OpenSource
-
New on ScienceOpen 🚀
All International Conferences on #Pharmacometrics (ICoP) Series publications from 2025 are now live on ScienceOpen.
🔗 Link to the 2025 ICoP Series publications in the first comment.
#Pharmacology #LifeSciences #QuantitativeBiology #OpenScience -
New on ScienceOpen 🚀
All International Conferences on #Pharmacometrics (ICoP) Series publications from 2025 are now live on ScienceOpen.
🔗 Link to the 2025 ICoP Series publications in the first comment.
#Pharmacology #LifeSciences #QuantitativeBiology #OpenScience -
The estimand framework, formalized in ICH E9(R1) regulatory guidance, provides a structured approach to define scientific objectives with precision. We apply the estimand framework to dose–exposure–response analyses. ... strategy to improve exposure–response analyses for dose selection, particularly when the relevant evidence includes data from multiple studies.
#estimand #exposure-response #dose-response #causal #pharmacometrics #pmx
-
The estimand framework, formalized in ICH E9(R1) regulatory guidance, provides a structured approach to define scientific objectives with precision. We apply the estimand framework to dose–exposure–response analyses. ... strategy to improve exposure–response analyses for dose selection, particularly when the relevant evidence includes data from multiple studies.
#estimand #exposure-response #dose-response #causal #pharmacometrics #pmx
-
The estimand framework, formalized in ICH E9(R1) regulatory guidance, provides a structured approach to define scientific objectives with precision. We apply the estimand framework to dose–exposure–response analyses. ... strategy to improve exposure–response analyses for dose selection, particularly when the relevant evidence includes data from multiple studies.
#estimand #exposure-response #dose-response #causal #pharmacometrics #pmx
-
The estimand framework, formalized in ICH E9(R1) regulatory guidance, provides a structured approach to define scientific objectives with precision. We apply the estimand framework to dose–exposure–response analyses. ... strategy to improve exposure–response analyses for dose selection, particularly when the relevant evidence includes data from multiple studies.
#estimand #exposure-response #dose-response #causal #pharmacometrics #pmx
-
🚀 New Open Access Article!
Advancing Pharmacometric Causal Inference (CPT Pharmacometrics & Systems Pharmacology 2026, e70202).We extend the solid pharmacometric toolkit that practitioners use daily by adding estimand framework and clear causal assumptions.
-
🔬📢 Das Graduiertenprogramm PharMetrX: Pharmacometrics & Computational Disease Modelling vergibt Stipendien (FU Berlin/Uni Potsdam) 📅 Bewerbung bis 6. Sept. 2025 – Start März 2026. 👉 Forschungsnähe, Mentoring, Industriepartner, Netzwerk www.pharmetrx.de #PhD #Stipendium #Pharmacometrics #FUBerlin
-
🔬📢 Das Graduiertenprogramm PharMetrX: Pharmacometrics & Computational Disease Modelling vergibt Stipendien (FU Berlin/Uni Potsdam) 📅 Bewerbung bis 6. Sept. 2025 – Start März 2026. 👉 Forschungsnähe, Mentoring, Industriepartner, Netzwerk www.pharmetrx.de #PhD #Stipendium #Pharmacometrics #FUBerlin
-
🔬📢 Das Graduiertenprogramm PharMetrX: Pharmacometrics & Computational Disease Modelling vergibt Stipendien (FU Berlin/Uni Potsdam) 📅 Bewerbung bis 6. Sept. 2025 – Start März 2026. 👉 Forschungsnähe, Mentoring, Industriepartner, Netzwerk www.pharmetrx.de #PhD #Stipendium #Pharmacometrics #FUBerlin
-
To fully realize the potential of our clinical trials, we must go beyond randomization, and use causal inference and pharmacometric modelling and simulation. Advancing both we show that non-linear mixed effects modelling implements the equivalent of standardization in causal inference. Dive into this if you're into #causal #causalinference #DAGs #pharmacometrics, or clinical development #stats.
-
To fully realize the potential of our clinical trials, we must go beyond randomization, and use causal inference and pharmacometric modelling and simulation. Advancing both we show that non-linear mixed effects modelling implements the equivalent of standardization in causal inference. Dive into this if you're into #causal #causalinference #DAGs #pharmacometrics, or clinical development #stats.
-
To fully realize the potential of our clinical trials, we must go beyond randomization, and use causal inference and pharmacometric modelling and simulation. Advancing both we show that non-linear mixed effects modelling implements the equivalent of standardization in causal inference. Dive into this if you're into #causal #causalinference #DAGs #pharmacometrics, or clinical development #stats.
-
To fully realize the potential of our clinical trials, we must go beyond randomization, and use causal inference and pharmacometric modelling and simulation. Advancing both we show that non-linear mixed effects modelling implements the equivalent of standardization in causal inference. Dive into this if you're into #causal #causalinference #DAGs #pharmacometrics, or clinical development #stats.
-
An oldie but goodie from Lewis Sheiner (1991) "The intellectual health of drug evaluation"
https://sci-hub.se/10.1038/clpt.1991.97
#pharmacometrics #phmx -
An oldie but goodie from Lewis Sheiner (1991) "The intellectual health of drug evaluation"
https://sci-hub.se/10.1038/clpt.1991.97
#pharmacometrics #phmx -
An oldie but goodie from Lewis Sheiner (1991) "The intellectual health of drug evaluation"
https://sci-hub.se/10.1038/clpt.1991.97
#pharmacometrics #phmx -
To prevent getting kicked off this instance, I actually did some #scicomm at last. It's an 'explainer' (with embedded @observablehq app h/t #QuartoPub!) for my paper in the upcoming CPT: #Pharmacometrics & Systems #Pharmacology special themed issue on Dose Optimization in Oncology.
https://precisionmethods.guru/posts/dose-optimization-trials-how-big/ -
To prevent getting kicked off this instance, I actually did some #scicomm at last. It's an 'explainer' (with embedded @observablehq app h/t #QuartoPub!) for my paper in the upcoming CPT: #Pharmacometrics & Systems #Pharmacology special themed issue on Dose Optimization in Oncology.
https://precisionmethods.guru/posts/dose-optimization-trials-how-big/ -
To prevent getting kicked off this instance, I actually did some #scicomm at last. It's an 'explainer' (with embedded @observablehq app h/t #QuartoPub!) for my paper in the upcoming CPT: #Pharmacometrics & Systems #Pharmacology special themed issue on Dose Optimization in Oncology.
https://precisionmethods.guru/posts/dose-optimization-trials-how-big/ -
Alright, then:
#pharmacometrics @justinwilkins @IDPharmacometrx @pascalschulthess @Sjtpharm @francois_mercier -
Alright, then:
#pharmacometrics @justinwilkins @IDPharmacometrx @pascalschulthess @Sjtpharm @francois_mercier -
Alright, then:
#pharmacometrics @justinwilkins @IDPharmacometrx @pascalschulthess @Sjtpharm @francois_mercier -
Alright, then:
#pharmacometrics @justinwilkins @IDPharmacometrx @pascalschulthess @Sjtpharm @francois_mercier -
Hello to all our new followers! We’re delighted that so many are interested in our modest little project.
Our mission is to make #Pharmacometrics accessible to everyone, regardless of where they live and how much money their institutions have. The gold standard tools in our field typically cost >100K US$ per year for a reasonable license. We cost US$ 0.
Help us change the world! (Well, our tiny corner of it in any case)
-
Hello to all our new followers! We’re delighted that so many are interested in our modest little project.
Our mission is to make #Pharmacometrics accessible to everyone, regardless of where they live and how much money their institutions have. The gold standard tools in our field typically cost >100K US$ per year for a reasonable license. We cost US$ 0.
Help us change the world! (Well, our tiny corner of it in any case)
-
Hello to all our new followers! We’re delighted that so many are interested in our modest little project.
Our mission is to make #Pharmacometrics accessible to everyone, regardless of where they live and how much money their institutions have. The gold standard tools in our field typically cost >100K US$ per year for a reasonable license. We cost US$ 0.
Help us change the world! (Well, our tiny corner of it in any case)
-
New #pharmacometrics question: Do you scrupulously reserve the term 'clearance' for THE clearance, "CL" (volume of plasma cleared per unit time)? Or do you ever use the word more generically to refer to a process or phenomenon, as in the phrase "receptor-mediated clearance"? @justinwilkins @IDPharmacometrx @pascalschulthess @Sjtpharm @francois_mercier
-
New #pharmacometrics question: Do you scrupulously reserve the term 'clearance' for THE clearance, "CL" (volume of plasma cleared per unit time)? Or do you ever use the word more generically to refer to a process or phenomenon, as in the phrase "receptor-mediated clearance"? @justinwilkins @IDPharmacometrx @pascalschulthess @Sjtpharm @francois_mercier
-
New #pharmacometrics question: Do you scrupulously reserve the term 'clearance' for THE clearance, "CL" (volume of plasma cleared per unit time)? Or do you ever use the word more generically to refer to a process or phenomenon, as in the phrase "receptor-mediated clearance"? @justinwilkins @IDPharmacometrx @pascalschulthess @Sjtpharm @francois_mercier
-
Regarding a 2-compartment model of mine (subcutaneous depot, plasma) a few clin pharm people are offering some odd complaints that a subQ depot isn't actually 'a compartment' "by convention". Is this view actually a thing? Is there some history behind it anyone could illuminate? Or is it just BS? #pharmacometrics @justinwilkins @francois_mercier @IDPharmacometrx @Sjtpharm
-
Regarding a 2-compartment model of mine (subcutaneous depot, plasma) a few clin pharm people are offering some odd complaints that a subQ depot isn't actually 'a compartment' "by convention". Is this view actually a thing? Is there some history behind it anyone could illuminate? Or is it just BS? #pharmacometrics @justinwilkins @francois_mercier @IDPharmacometrx @Sjtpharm
-
Regarding a 2-compartment model of mine (subcutaneous depot, plasma) a few clin pharm people are offering some odd complaints that a subQ depot isn't actually 'a compartment' "by convention". Is this view actually a thing? Is there some history behind it anyone could illuminate? Or is it just BS? #pharmacometrics @justinwilkins @francois_mercier @IDPharmacometrx @Sjtpharm
-
Regarding a 2-compartment model of mine (subcutaneous depot, plasma) a few clin pharm people are offering some odd complaints that a subQ depot isn't actually 'a compartment' "by convention". Is this view actually a thing? Is there some history behind it anyone could illuminate? Or is it just BS? #pharmacometrics @justinwilkins @francois_mercier @IDPharmacometrx @Sjtpharm
-
#ChatGPT applications in #Pharmacometrics from Peter Bloomingdale. Are pharmacometrician jobs in danger from #AI?
TL;DR LOL no. But a fun read.
-
#ChatGPT applications in #Pharmacometrics from Peter Bloomingdale. Are pharmacometrician jobs in danger from #AI?
TL;DR LOL no. But a fun read.
-
#ChatGPT applications in #Pharmacometrics from Peter Bloomingdale. Are pharmacometrician jobs in danger from #AI?
TL;DR LOL no. But a fun read.
-
Our colleagues at LAP&P are hosting a target-mediated drug disposition #TMDD course using #nlmixr2 at #PAGE2023 in A Coruña, Spain!
This is your chance to see nlmixr2 put through its paces in real-world #pharmacometrics by a world-class consulting team.
-
@AbuMirchi @damiacer Perhaps they’d like to fund development of an open source #NLME #Pharmacometrics model development tool
-
@AbuMirchi @damiacer Perhaps they’d like to fund development of an open source #NLME #Pharmacometrics model development tool
-
@AbuMirchi @damiacer Perhaps they’d like to fund development of an open source #NLME #Pharmacometrics model development tool
-
Very nice piece of work by Jim Rogers and colleagues. Essential reading for any pharmacometrician. #Pharmacometrics #CausalInference
-
Very nice piece of work by Jim Rogers and colleagues. Essential reading for any pharmacometrician. #Pharmacometrics #CausalInference
-
Very nice piece of work by Jim Rogers and colleagues. Essential reading for any pharmacometrician. #Pharmacometrics #CausalInference
-
Well, it's nice to know AI has limitations. 😃
(This code is largely nonsense.)
-
Well, it's nice to know AI has limitations. 😃
(This code is largely nonsense.)